(Total Views: 632)
Posted On: 10/24/2020 3:59:32 PM
Post# of 154804
Tech Guru - always enjoy your posts. One further argument from my end:
Unblinding the data does not equate with stopping the trial. The trial will continue.
So, to me, the decision comes more about the risks of unblinding:
1. p-value penalty. Not concerned with this, per my prior post.
2. "the hanging sword of misuse and the trial being rendered invalid" - I'm not sure what this is about, or how we mitigate it.
Benefits (offsetting the risks): publicity; faster future trial enrollment; getting on the radar of foreign countries sooner; learning sooner if something might be fouled up that would cause us to take a different tack (this could be super important, saving us time and money); potential for higher stock price now, helping us raise capital.
Unblinding the data does not equate with stopping the trial. The trial will continue.
So, to me, the decision comes more about the risks of unblinding:
1. p-value penalty. Not concerned with this, per my prior post.
2. "the hanging sword of misuse and the trial being rendered invalid" - I'm not sure what this is about, or how we mitigate it.
Benefits (offsetting the risks): publicity; faster future trial enrollment; getting on the radar of foreign countries sooner; learning sooner if something might be fouled up that would cause us to take a different tack (this could be super important, saving us time and money); potential for higher stock price now, helping us raise capital.
(2)
(1)
